GLP-1(S)

Semaglutide is a 94% sequence-homologous GLP-1 receptor agonist developed through strategic amino acid substitution and C18 fatty diacid acylation, engineered for extended half-life and once-weekly dosing in research models. As a GLP-1R agonist, it drives glucose-dependent insulin secretion, suppresses glucagon release, reduces gastric motility, and activates hypothalamic satiety centers via direct CNS receptor engagement — producing robust and sustained reductions in caloric intake and body adiposity in preclinical and clinical settings.

Phase 3 research has demonstrated up to 15% mean body weight reduction alongside significant improvements in HbA1c, cardiovascular risk markers, and hepatic steatosis, establishing semaglutide as one of the most extensively studied and pharmacologically characterized incretin-based compounds in modern metabolic research.

Specifications:

• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: −20°C

For Research Use Only.